Telix Pharmaceuticals Limited (ASX:TLX)

Telix Pharmaceuticals Revenue

In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M USD with 55.61% growth. Telix Pharmaceuticals had revenue of $413.44M in the half year ending December 31, 2025, with 115.29% growth.

• Revenue: $803.79M
• Revenue Growth: +55.61%
• P/S Ratio: 4.15
• Revenue / Employee: $678.88K
• Employees: 1,184
• Market Cap: 5.00B AUD

Revenue Chart

* This company reports financials in USD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	803.79M	287.24M	55.61%
Dec 31, 2024	516.55M	183.57M	55.13%
Jan 1, 2024	332.98M	224.17M	206.01%
Dec 31, 2022	108.81M	103.29M	1,870.12%
Dec 31, 2021	5.52M	1.50M	37.33%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

May 7, 2026

Data Sources Report a data error